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The Journal of Immunology
N-Arachidonoyl Dopamine Modulates Acute Systemic
Inflammation via Nonhematopoietic TRPV1
Samira K. Lawton,*,† Fengyun Xu,† Alphonso Tran,† Erika Wong,† Arun Prakash,†
Mark Schumacher,† Judith Hellman,†,‡,1 and Kevin Wilhelmsen†,1
N-Arachidonoyl dopamine (NADA) is an endogenous lipid that potently activates the transient receptor potential vanilloid 1
(TRPV1), which mediates pain and thermosensation. NADA is also an agonist of cannabinoid receptors 1 and 2. We have reported
that NADA reduces the activation of cultured human endothelial cells by LPS and TNF-a. Thus far, in vivo studies using NADA
have focused on its neurologic and behavioral roles. In this article, we show that NADA potently decreases in vivo systemic
inflammatory responses and levels of the coagulation intermediary plasminogen activator inhibitor 1 in three mouse models of
inflammation: LPS, bacterial lipopeptide, and polymicrobial intra-abdominal sepsis. We also found that the administration of
NADA increases survival in endotoxemic mice. Additionally, NADA reduces blood levels of the neuropeptide calcitonin gene-
related peptide but increases the neuropeptide substance P in LPS-treated mice. We demonstrate that the anti-inflammatory
effects of NADA are mediated by TRPV1 expressed by nonhematopoietic cells and provide data suggesting that neuronal TRPV1
may mediate NADA’s anti-inflammatory effects. These results indicate that NADA has novel TRPV1-dependent anti-inflammatory
properties and suggest that the endovanilloid system might be targeted therapeutically in acute inflammation. The Journal of
Immunology, 2017, 199: 1465–1475.
T
he endogenous lipid N-arachidonoyl dopamine (NADA)
is composed of an arachidonic acid backbone conjugated
to a dopamine moiety (1). NADA is a putative endocanna-
binoid and possesses activity via the G protein–coupled cannabinoid
receptors (2, 3). NADA has also been classified as an endovanilloid,
which is a group of endogenous activators of the transient receptor
potential vanilloid 1 (TRPV1) and include the endocannabinoid
anandamide (AEA) and a variety of lipoxygenase products (4–6).
TRPV1, a nonselective cation channel, is primarily known for its role
in sensing pain and temperature. Of the known endovanilloids,
NADA is the most potent activator of TRPV1 and is considered to be
a principal endogenous TRPV1 ligand (1, 5, 7, 8). TRPV1 is also
activated by a variety of noxious insults, including heat . 42˚C,
low pH, and capsaicin, the active ingredient in chili peppers (5).
TRPV1 is highly expressed in the peripheral nervous system,
specifically in a subset of small-diameter primary sensory neurons
in trigeminal nerve and dorsal root ganglia that detect noxious
stimuli and in the inferior (nodose) ganglion of the vagus nerve
(9–13). The peripheral terminals of TRPV1-expressing noci-
ceptors innervate most organs and tissues. TRPV1 expressed in the
peripheral nervous system functions to integrate multiple noxious
stimuli, ultimately leading to the release of neuropeptides, such as
calcitonin gene–related peptide (CGRP) and substance P. These
neuropeptides elicit pain and neurogenic inflammatory responses
(14–18). TRPV1 is also expressed in the CNS, including the spinal
cord, striatum, hippocampus, cerebellum, and amygdala (19–23).
Finally, TRPV1 is found in nonneuronal cells, including leukocytes,
smooth muscle cells, and endothelial cells (11, 17, 24–27). In this
regard, TRPV1 activation has been reported to regulate the acti-
vation and proinflammatory properties of CD4+ T cells (28)
NADA and TRPV1 have overlapping distributions, because
NADA has been detected in the striatum, cerebellum, hippocam-
pus, thalamus, brainstem, and dorsal root ganglia (7, 19, 20, 23,
29). Moreover, NADA has been proposed to modulate neuronal
homeostasis by reducing or inducing cation influx via activation of
cannabinoid receptors and TRPV1, respectively (1, 30). In addition
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to its neurologic and behavioral effects, limited studies suggest that
NADA has anti-inflammatory effects on nonneuronal cells, such as
astrocytes, leukocytes, and endothelial cells (2, 24, 31–34).
We previously found that treatment with NADA reduces the acti-
vation of cultured endothelial cells by TNF-a, as well as by bacterial
lipopeptides (TLR2 agonists) and LPS (endotoxin, TLR4 agonist)
(24). Furthermore, our data using pharmacological inhibitors sug-
gested that the activities of NADA may be mediated through can-
nabinoid (CB) receptors and TRP channels. Thus, we proposed that
NADA may fine-tune the inflammatory activation of endothelial cells
through TRPs, which are known to have a similar function in neurons
(24). These studies led us to hypothesize that NADA may moderate
sepsis-induced inflammation. The majority of the in vivo work on
NADA has focused on its neurologic and behavioral effects, and
NADA’s effects on inflammation have not been characterized (2, 35–
38). Although there are mixed studies suggesting that TRPV1 acti-
vation affects inflammation in models of sepsis, to our knowledge, no
prior study has investigated in vivo the role of NADA or the NADA–
TRPV1 axis in sepsis (17, 27, 39, 40). Therefore, we tested the
hypothesis that the administration of NADA would reduce acute
systemic inflammation in sepsis via activation of TRPV1. We find that
treatment with NADA reduces systemic inflammation in toxicity and
infection models of sepsis and improves survival of endotoxemic
mice. We determine that NADA’s anti-inflammatory effects depend
upon TRPV1 expressed outside of the hematopoietic compartment.
We also find that the ability of NADA to regulate systemic inflam-
mation does not require leukocyte or endothelial TRPV1, pointing to
a potential role for neuronal TRPV1 expression in the anti-
inflammatory effects of NADA.
Materials and Methods
Mice
C57BL/6J wild-type (WT), B6.129 3 1-Trpv1tm1Jul/J (Trpv12/2), and
congenic B6.SJL-Ptprca (CD45.1+) mice were purchased from The Jackson
Laboratory (Bar Harbor, ME). Experiments used 8-wk-old male or female
mice. The University of California, San Francisco Institutional Animal Care
and Use Committee approved all animal studies, and experiments were
performed in accordance with the Public Health Service Policy on the
Humane Care and Use of Laboratory Animals. Unless otherwise noted, adult
mice were euthanized using CO2 asphyxiation, followed by bilateral tho-
racotomies and exsanguination by direct cardiac puncture.
Treatment of mice with LPS, Pam3Cys, NADA, AEA,
2-arachidonoyl glycerol, and capsaicin
In studies focused on the effects of NADA and TRPV1 on acute systemic
inflammation, WT and Trpv12/2 mice were injected i.v. (challenged) with
Pam3Cys (10 mg/kg; EMC Microcollections, Tubingen, Germany), LPS
(5 mg/kg; Sigma-Aldrich, St. Louis, MO), or 0.9% saline (carrier for LPS
and Pam3Cys). Five minutes later, they were treated i.v. with vehicle alone
(5% Tween-20 in PBS) or with NADA (1–10 mg/kg), AEA (10–40 mg/kg),
2-arachidonoyl glycerol (2-AG; 10 mg/kg), or capsaicin (0.2 mg/kg)
(Tocris, Minneapolis, MN) dissolved in vehicle. Unless otherwise noted,
whole blood was collected via cardiac puncture for cytokine analysis 2 h
postinjection using citrate as the anticoagulant. In each experiment, at least
four mice were used per condition, and experiments were performed at
least twice in different weeks. The doses of Pam3Cys and LPS used were
established in pilot dose-response studies.
In separate experiments, we assessed the effects of NADA administration
on survival of endotoxemic mice. Eight-week-old WT male mice were
challenged with LPS (7 mg/kg, i.p.) and then received two i.v. doses of
NADA (5 mg/kg) or carrier. The first dose of NADAwas given 5 min after
LPS challenge, and the second was given at t = 2 h. Mice were monitored at
4 and 8 h and then every 8 h through 48 h. Moribund mice were euthanized
and counted as nonsurvivors, as required by our Institutional Animal Care
and Use Committee. A moribund state was defined by inanition, the lack of
response to gentle shaking of the cage, and the inability of the mice to right
themselves when placed on their sides. Individuals who were blinded to the
treatment groups monitored mice and made decisions about whether they
were moribund and required euthanasia.
Immunoassays and MTT assay
IL-6, CCL-2, IL-10, and plasminogen activator inhibitor (PAI)-1 levels were
quantified in mouse plasma samples by ELISA (R&D Systems, Minne-
apolis, MN and Innovative Research, Novi, MI). Substance P and CGRPa/b
levels were quantified in mouse plasma samples by enzyme immunoassay
(Enzo Life Sciences, Farmingdale, NY and Cayman Chemicals, Ann Arbor,
MI, respectively), and absorbance was read using a FLUOstar OPTIMA
fluorescent plate reader (BMG Labtech, Cary, NC). Plasma samples were
also analyzed for cytokines with a Bio-Plex Pro Mouse 23-Plex Group 1
magnetic bead–based multiplex assay (Bio-Rad, Hercules, CA) using a
MAGPIX instrument and xPONENT analysis software (Luminex, Austin,
TX), according to the manufacturers’ specifications. The lower limit of
detection and intra-assay percentage coefficient of variability (CV) for this
panel of analytes were IL-1b = 47.68 pg/ml (4.8% CV), TNF-a = 13.62
pg/ml (4.7% CV), IL-10 = 4.99 pg/ml (3.4% CV), CCL2 = 35.82 pg/ml
(4.7% CV), CCL3 = 1.53 pg/ml (4.3% CV), CCL4 = 2.46 pg/ml (3.9%
CV), CCL5 = 1.69 pg/ml (3.4% CV), IL-12p40 = 5.74 pg/ml (3.2% CV),
and CXCL1 = 3.54 pg/ml (1.9% CV). MTT assays were performed to
assess cell viability, as described (24).
Liquid chromatography–tandem mass spectrometry
An analytical liquid chromatography–tandem mass spectrometry (LC-MS/
MS) method to detect endocannabinoids in plasma was developed at
Cayman Chemical. Plasmas were collected 0, 5, 10, 30, or 60 min after i.v.
administration of NADA to WT mice. Plasma samples were analyzed by
LC-MS/MS using a NADA standard prepared at Cayman Chemical, as
described (24).
Cecal ligation and puncture
Cecal ligation and puncture (CLP) was performed on 8-wk-old WT female
mice, as described (41). Briefly, mice were anesthetized with isoflurane and
then were administered a 1-ml bolus of saline s.c. to account for fluid loss.
The abdominal cavity was opened, and the cecum was exteriorized and
ligated midway between the tip and the ileocecal junction. The cecum was
punctured once using a 20-gauge needle, and light pressure was applied to
extrude a small amount of stool from the puncture site. The cecum was
replaced into the abdomen, the incision was closed using a silk suture, and
the skin was closed using a clip stapler. Sham mice underwent the identical
procedure, but without the cecal ligation or puncture. NADA (10 mg/kg,
i.v.; Cayman Chemicals) or vehicle (5% Tween-20 in PBS) was admin-
istered to mice immediately after surgery and again 2 h postoperatively.
For analgesia, bupivacaine was applied locally to the incision site during
closure, and buprenorphine was administered s.c. immediately prior to
incision and again at 4 h. Mice were placed on a warming pad throughout
surgery and postoperatively until they were fully recovered.
Preparation of primary murine cells
PBMCs were isolated from murine whole blood collected in citrate by
gradient centrifugation using Lymphoprep (Axis-Shield, Oslo, Norway), as
per the manufacturer’s instructions. Primary peritoneal cells were isolated
from adult mice as described (42). Primary lung endothelial cells and
microglia were prepared from 6–7-d-old mouse pups immediately after de-
capitation, as described (43–45). The purity of the cell populations was ver-
ified by flow cytometry, as described below. Endothelial cells from WT and
Trpv12/2 mice cells were 90.3 and 90.9% pure, respectively. Bone marrow
was isolated from 8-wk-old WT and Trpv12/2 male donor mice as described,
and erythrocytes were lysed using RBC Lysis Buffer (Sigma-Aldrich) (46).
Bone marrow chimera studies
For the generation of chimeric mice, bone marrow hematopoietic cells were
isolated and suspended in PBS to a final concentration of 1 3 107 cells per
milliliter (46). Bone marrow chimeras were produced by lethally irradi-
ating recipient congenic CD45.1 mice with a split dose of 1100 rad, fol-
lowed by i.v. administration of 2 3 106 WT or Trpv12/2 donor bone
marrow cells. To allow sufficient recovery time from the bone marrow
transplantation, experiments were performed 8–9 wk after irradiation.
Recipient mice were fed antibiotic pellets containing sulfamethoxazole
and trimethoprim 1 wk prior to and 3 wk after radiation. Bone marrow
engraftment was verified by flow cytometry, as described below. Chimeras
were challenged with LPS and treated with NADA, as described above.
Ex vivo NADA and inflammatory agonist treatments
Endothelial cells were grown to confluence in 48-well plates before agonist
treatment. Microglia were plated at 83 104 cells per well in 48-well plates
and used 2 d after plating. In all experiments, cells were preincubated with
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NADA or vehicle (ethanol) at the indicated concentrations for 1 h prior to
and continuously during the inflammatory agonist treatment. Pam3Cys
(10 mg/ml) or LPS (10 ng/ml) was added for 6 h. Preparations of Pam3Cys
contained ,0.002 EU/ml endotoxin based on the kinetic turbidimetric
Limulus amebocyte lysate assay.
Flow cytometry
Mice were euthanized, whole blood was collected by cardiac puncture, and
erythrocytes were lysed using RBC Lysis Buffer. Cultured primary murine
cells were detached with Accutase (Innovative Cell Technologies, San
Diego, CA). Cells were passed through a 70-mm cell strainer, counted, and
aliquoted at 1 3 106 cells per sample. Cells were washed using PBS
without Ca2+ and Mg2+ and incubated with LIVE/DEAD violet fluorescent
reactive dye (Thermo Fisher Scientific, Waltham, MA) in PBS for 30 min
at 4˚C to assess cell viability. Cells were then washed using Flow
Cytometry Staining Buffer (FCSB; R&D Systems) and incubated with rat
anti-mouse IgG (1 mg; Thermo Fisher Scientific) in FCSB for 15 min at
4˚C. Next, cells isolated from whole blood were incubated for 30 min at
4˚C with specific Ab (1 mg) or isotype control (1 mg). Samples were
washed twice with FCSB and then fixed using BD Cytofix (250 ml; BD
Biosciences, San Jose, CA) for 30 min at 4˚C. Samples were washed once
more with FCSB and analyzed by flow cytometry (BD LSR II Flow
Cytometer; BD Biosciences). Abs used were purchased from BD Biosciences
unless otherwise noted: FITC-mouse anti-mouse CD45.1, allophycocyanin-
mouse anti-mouse CD45.2, FITC-mouse IgG2a k, allophycocyanin-mouse
IgG2a k, FITC-rat anti-mouse CD102, PE-rat anti-mouse CD31, FITC-rat
anti-mouse IgG2a k, PE-rat anti-mouse IgG2a k, and Alexa Fluor 750–rat
anti-mouse aM/CD11b (R&D Systems).
Statistics
Survival curves were compared using a log-rank (Mantel–Cox) test. All
other data were analyzed using a two-tailed Mann–Whitney U tests. A
p value ,0.05 was considered statistically significant for all data. With the
exception of the survival studies, the data in graphs are presented as mean
6 SD. All experiments were repeated at least twice. Group sizes are in-
dicated in the figure legends.
Results
NADA reduces systemic inflammation and PAI-1 levels in mice
challenged with LPS or Pam3Cys
To investigate the contribution of NADA to systemic inflammation
and coagulopathy, we challenged mice with LPS (5 mg/kg, i.v.)
immediately prior to treatment with NADA (1, 5, and 10 mg/kg,
i.v.). NADA doses of 5 and 10 mg/kg significantly reduced plasma
concentrations of IL-6 and CCL2 at t = 2 h after LPS challenge
(Fig. 1A, 1B). In comparison with vehicle-treated control mice,
NADA also reduced the LPS-induced upregulation of PAI-1
(Fig. 1C), an antifibrinolytic factor that is associated with an
increased incidence of organ failure and death in sepsis (47). NADA
alone did not affect baseline levels of inflammatory mediators or
PAI-1 (data not shown). These results are consistent with data that we
obtained using a 23-plex immunoassay, in which NADA decreased
LPS-induced production of the proinflammatory cytokines IL-1b,
TNF-a, CCL2, CCL3, CCL4, CCL5, and IL-12p40 while signifi-
cantly increasing the levels of the anti-inflammatory cytokine IL-10
(data not shown).
Although LPS is found exclusively on Gram-negative bacteria,
TLR2-activating lipoproteins are expressed by Gram-positive and
Gram-negative bacteria (48). To test whether NADA reduces TLR2-
mediated inflammation, we challenged mice with Pam3Cys (10 mg/kg,
i.v.), a TLR2 ligand, and immediately thereafter administered NADA
(10 mg/kg, i.v.). Similar to LPS, administration of NADA reduced
levels of IL-6, CCL2, and PAI-1, but increased IL-10 levels in
plasma 2 h after Pam3Cys challenge (Supplemental Fig. 1).
NADA administration increases survival in endotoxemic mice
To test the hypothesis that the administration of NADAwould have
a functional effect on outcomes of acute systemic inflammation, we
assessed the effects of NADA on 48-h survival of mice challenged
with LPS (7mg/kg, i.p.). Survival was significantly higher inNADA-
treated mice versus carrier-treated mice (Fig. 1D). Overall survival
was higher and median survival times were longer in NADA-treated
mice (48-h survival 31.7%, median survival 40 h) versus carrier-
treated mice (48-h survival 14.6%, median survival 24 h).
NADA has a short half-life in the circulation
Wemeasured plasma NADA levels at intervals through 60min after
treatment of mice with NADA (10 mg/kg, i.v.) using LC-MS/MS.
Although the half-maximal concentration of NADA was achieved
at 2.7 min, suggesting rapid clearance from the blood, NADA levels
remained at 100 ng/ml at the final time point of 60 min
(Supplemental Fig. 2). It is unclear whether NADA is catabolized
or distributed into tissues.
NADA promotes an anti-inflammatory cytokine profile and
reduces PAI-1 in the CLP model of sepsis in mice
We assessed the effects of NADA in a CLP model of polymicrobial
intra-abdominal sepsis to determine its effects during active
infection. We administered NADA immediately after CLP surgery
and again 2 h later, and then quantified plasma cytokines and
PAI-1 at 6 h. NADA treatment significantly reduced IL-6, CCL2,
and PAI-1 levels and increased IL-10 levels (Fig. 2). Mice that
underwent sham surgery had background levels of cytokines in the
presence or absence of NADA. Thus, NADA reduces the systemic
proinflammatory response during an active infection.
NADA’s anti-inflammatory activity in vivo requires TRPV1
To determine the role of TRPV1 expression in the anti-inflammatory
effects of NADA, we compared the responses of WT and Trpv12/2
mice challenged with LPS (5 mg/kg, i.v.) or Pam3Cys (10 mg/kg,
i.v.), immediately followed by NADA (10 mg/kg, i.v.) or vehicle. In
contrast to WT mice, the administration of NADA had no effect on
plasma levels of IL-6, CCL2, IL-10, or PAI-1 in Trpv12/2 mice
challenged with LPS or Pam3Cys (Fig. 3). NADA alone did not
affect baseline levels of inflammatory mediators or PAI-1 in WT
or Trpv12/2 mice (data not shown). These data indicate that
TRPV1 mediates the anti-inflammatory effects of NADA in LPS-
and Pam3Cys-treated mice.
Capsaicin and AEA reduce inflammation and PAI-1 in
endotoxemic mice
NADA activates CB receptors (CBRs) in addition to TRPV1, and
our prior study supported a dominant role for the CBRs in the anti-
inflammatory effects of NADA in human endothelial cells (24). To
determine whether TRPV1 activation might affect LPS-induced
systemic inflammation independently of CBR activation, we stud-
ied the effects of capsaicin, a TRPV1-specific agonist that is devoid
of effects on CBR 1 (CB1R) or CBR 2 (CB2R). Similar to NADA,
the administration of capsaicin (0.2 mg/kg, i.v.) reduced IL-6, CCL2,
and PAI-1 levels and increased IL-10 levels in LPS-treated mice
(Fig. 4A–D). Capsaicin doses of 0.01 or 0.05 mg/kg had no effect on
LPS-induced cytokines or PAI-1 (data not shown), and capsaicin
alone did not affect baseline expression of these mediators.
We also tested the effects of the endocannabinoid AEA, which,
like NADA, activates CBRs and TRPV1 (6, 49). However, AEA is
a less potent TRPV1 agonist than NADA (36). A high dose of
AEA (40 mg/kg) abrogated LPS-induced upregulation of IL-6,
CCL2, and PAI-1 and increased IL-10 (Fig. 4E–H). The effects
of AEA on cytokines and PAI-1 were less pronounced than those
of NADA or capsaicin, and these effects were not observed with
lower doses of AEA (10 or 20 mg/kg; data not shown). Treatment
with the endocannabinoid 2-AG, which activates CBRs but not
TRPV1, did not affect LPS-induced inflammation (Supplemental
Fig. 3). Our data showing anti-inflammatory effects of capsaicin
The Journal of Immunology 1467
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and AEA support the hypothesis that TRPV1 activation has anti-
inflammatory effects in sepsis.
NADA exerts its anti-inflammatory effects in vivo via
nonhematopoietic TRPV1
TRPV1 is expressed in multiple cell lineages, including hemato-
poietic and nonhematopoietic cells. Therefore, we used bonemarrow
chimeras to determine the role of hematopoietic versus non-
hematopoietic TRPV1 expression in NADA’s anti-inflammatory
properties. We transplanted Trpv12/2 (CD45.2+) bone marrow
cells into irradiated WT (CD45.1+) recipient mice to generate mice
that lack TRPV1 expression in hematopoietic cells (Trpv12/2 →
WT). We also generated reverse chimeras that exclusively express
TRPV1 in hematopoietic cells by transplanting WT (CD45.1+)
bone marrow into irradiated Trpv12/2 (CD45.2+) recipients (WT→
Trpv12/2). As controls, WT (CD45.1+) bone marrow was trans-
planted into irradiated WT (CD45.2+) recipients (WT → WT), and
Trpv12/2 bone marrow cells were transplanted into Trpv12/2 re-
cipients (Trpv12/2 → Trpv12/2). We verified bone marrow en-
graftment by flow cytometry, with .95% of leukocytes staining as
donor cells (data not shown). We then challenged mice with LPS
(5 mg/kg, i.v.) and treated them with NADA (10 mg/kg, i.v.). In
contrast to our results in global Trpv12/2 mice, NADA reduced
levels of IL-6, CCL2, and PAI-1, and increased IL-10 levels, in
mice lacking TRPV1 expression in their hematopoietic cells
(Trpv12/2 → WT) (Fig. 5). Furthermore, in mice lacking TRPV1
expression outside of the bone marrow (WT → Trpv12/2), NADA
had no effect on levels of IL-6, CCL-2, PAI-1, or IL-10 (Fig. 5).
These data indicate that NADA does not require hematopoietic
TRPV1 to exert its anti-inflammatory effects in vivo in endo-
toxemic mice.
NADA exerts its anti-inflammatory effects independently of
TRPV1 in cultured primary murine hematopoietic cells and
endothelial cells
Because our bone marrow chimera studies suggested that NADA
mediates its anti-inflammatory effects via nonhematopoietic
TRPV1, we performed ex vivo studies using cultured myeloid cells
and endothelial cells prepared from WT and Trpv12/2 mice. For
each of these studies, cells were incubated for 1 h with NADA and
then stimulated with LPS or Pam3Cys. NADA treatment reduced
IL-6 production induced by LPS or Pam3Cys in WT and Trpv12/2
bone marrow cells (Fig. 6A, shown for LPS). Similar results were
obtained in PBMCs and thioglycollate-elicited peritoneal macro-
phages from WT and Trpv12/2 mice (data not shown). Because
irradiation may not fully deplete brain-resident microglia, we were
concerned that the results of our bone marrow chimera studies
could have been due to the residual TRPV1-expressing microglia
in irradiated WT mice transplanted with Trpv12/2 marrow (50).
Similar to bone marrow cells, PBMCs, and peritoneal macro-
phages, NADA treatment reduced the LPS-induced upregulation
of IL-6 in microglia from WT and Trpv12/2 mice (Fig. 6B). Fi-
nally, we tested the effects of NADA on LPS-induced activation of
primary lung endothelial cells isolated from WT and Trpv12/2
mice. NADA induced a comparable decrease in LPS-induced IL-6
secretion by endothelial cells from Trpv12 /2 and WT mice
FIGURE 1. NADA reduces circulating IL-6, CCL2, and PAI-1 levels and increases survival in endotoxemic mice. (A–C) WT mice were challenged i.v.
with LPS or carrier and immediately thereafter were treated i.v. with NADA (1, 5, or 10 mg/kg) or vehicle. Levels of IL-6 (A), CCL2 (B), and PAI-1 (C)
were quantified in plasma after 2 h (n = 4 mice per group). *p , 0.05 LPS-treated mice in the presence or absence of NADA, Mann–Whitney U test. (D)
Survival was followed over a 48-h period in WT mice challenged i.p. with LPS (7 mg/kg) and treated with two i.v. doses of NADA (5 mg/kg) or carrier at
t = 5 min and 2 h (n = 41 mice per group). *p , 0.0287, log-rank test.
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(Fig. 6C). Collectively, these ex vivo data suggest that the effects
of NADA on acute inflammation are not mediated through TRPV1
expressed by endothelial cells, cells derived from the hematopoietic
lineage, or microglia. Furthermore, they suggest that NADA re-
duces inflammatory activation of these endothelial cells, mono-
cytes, macrophages, and microglia through TRPV1-independent
mechanisms. This is consistent with our prior work showing that
CB1R and CB2R antagonists block the anti-inflammatory effects of
NADA on primary human endothelial cells (24).
NADA modulates neuropeptide expression via TRPV1
We hypothesized that NADA may exert its anti-inflammatory ef-
fects via the release of the neuropeptides CGRP and substance P,
both of which are released by TRPV1-expressing neurons in
sensory ganglia. We quantified plasma levels of substance P
(Fig. 7A) and CGRP (Fig. 7B) in mice treated with NADA and
LPS. NADA augmented substance P levels in carrier-treated and
LPS-treated WT mice. The augmentation of substance P by
NADA was greater in LPS-treated mice compared with carrier-
treated mice. In contrast to WT mice, NADA had no effects on
substance P levels in LPS-treated or carrier-treated Trpv12/2
mice. LPS alone slightly, but significantly, reduced substance P
levels in WT and Trpv12/2 mice. In contrast, LPS alone induced
CGRP in WT and Trpv12/2 mice. The upregulation of CGRP by
LPS alone was more pronounced in WT mice compared with
Trpv12/2 mice. Finally, NADA dramatically decreased CGRP
levels in LPS-treated WT mice but had no effect on CGRP levels
in LPS-treated Trpv12/2 mice. Capsaicin had similar effects as
NADA on neuropeptide release (data not shown).
Discussion
We have provided the first evidence, to our knowledge, that the
endocannabinoid/endovanilloid NADA abates acute systemic in-
flammation in vivo, in a TRPV1-dependent manner. Treatment
with NADA reduces plasma levels of proinflammatory cytokines
and PAI-1 and increases levels of the anti-inflammatory cytokine
IL-10 in mice with intra-abdominal sepsis induced by CLP and
following challenge with microbial TLR2 and TLR4 agonists.
Furthermore, the administration of NADA increases survival in
endotoxemic mice. NADA has mixed effects on circulating levels
of the neuropeptides: it reduces CGRP but augments substance P
in endotoxemic mice. Our data in Trpv12/2 bone marrow
chimeras suggest that TRPV1 expressed in nonhematopoietic cells
mediates the anti-inflammatory effects of NADA. These data, in
conjunction with our ex vivo data using microglia, PBMCs,
peritoneal macrophages, bone marrow cells, and endothelial cells,
raise the intriguing possibility that NADA exerts its anti-
inflammatory effects in vivo via neuronal TRPV1. We provide
further evidence of an anti-inflammatory effect of TRPV1 acti-
vation by showing that capsaicin, a specific TRPV1 agonist, and
AEA, a weak TRPV1 agonist, also reduce LPS-induced systemic
inflammation. During septic shock, the excessive production of
proinflammatory mediators and the failure to appropriately resolve
inflammation, in conjunction with dysregulation of coagulation
FIGURE 2. NADA modulates cytokines and PAI-1 in a CLP model of sepsis. WT mice underwent CLP or sham surgeries and were given NADA or
vehicle i.v. immediately after surgery and again 2 h later. Levels of IL-6 (A), CCL2 (B), IL-10 (C), and PAI-1 (D) were quantified in plasmas 6 h after
surgery (n = 4–10 mice per group). ***p , 0.001, ****p , 0.0001, CLP mice in the presence or absence of NADA, Mann–Whitney U test.
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FIGURE 3. TRPV1 mediates NADA
anti-inflammatory activity in mice
challenged with LPS or Pam3Cys. WT
and Trpv12/2 mice were challenged i.v.
with LPS (A–D) or Pam3Cys (E–H) and
immediately thereafter were treated i.v.
with NADA or vehicle (n = 4 mice per
group). Plasma concentrations of IL-6
(A and E), CCL2 (B and F), IL-10 (C
and G), and PAI-1 (D and H) were
quantified at 2 h. There were no sig-
nificant differences between WT and
Trpv12/2 mice challenged with LPS or
Pam3Cys in the absence of NADA or
in WT and Trpv12/2 mice treated
with NADA alone (data not shown).
**p , 0.01, LPS-challenged (A–D) or
Pam3Cys-challenged (E–H) WT mice
treated with NADA versus carrier,
Mann–Whitney U test. NS, no signifi-
cant difference between LPS-challenged
or Pam3Cys-challenged Trpv12/2 mice
treated with NADA versus carrier.
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pathways, lead to organ failure, the most common cause of demise
in this high-mortality syndrome (51–53). We speculate that the
NADA–TRPV1 axis may protect against sepsis-induced compli-
cations, such as multiple organ failure and death, by abrogating
the positive-feedback loop that propagates pathological inflam-
mation by reducing proinflammatory cytokines and PAI-1, which
is an inhibitor of fibrinolysis that facilitates clot persistence.
Collectively, our results suggest that the endovanilloid system, and
particularly TRPV1, represents a novel potential therapeutic target
for the treatment of disorders characterized by dysregulated acute
inflammation, such as sepsis.
Because NADA is putatively the principal endogenous TRPV1
agonist, we sought to determine the contribution of TRPV1 to the
immunomodulatory effects of NADA in mice. The effects of
NADA on circulating levels of cytokines, PAI-1, and neuropeptides
induced by challenge with TLR agonists were absent in Trpv12/2
mice, indicating that TRPV1 is required to elicit these early pa-
rameters of systemic and neuroinflammation. Functional TRPV1
expressed by a number of nonneuronal cell populations has been
reported to regulate immune responses (24–28, 39, 40, 54). How-
ever, our data with bone marrow chimeras suggest that TRPV1
expressed outside of the hematopoietic compartment mediates
NADA’s anti-inflammatory effects in endotoxemic mice. This is
further supported by our ex vivo data that bone marrow, peritoneal
cells, PBMCs, and microglia from Trpv12/2 mice all retain equiv-
alent responsiveness to the anti-inflammatory properties of NADA
compared with cells from WT mice. Similarly, our ex vivo data
using primary endothelial cells suggest that endothelial TRPV1 is
not responsible for NADA’s in vivo anti-inflammatory properties in
mice. We previously reported that CBRs may mediate the anti-
inflammatory effects of NADA in human endothelial cells,
suggesting that CB1R and/or CB2R may be responsible for the
anti-inflammatory effects of NADA on leukocyte and endothelial
cell populations (24). These results support the notion that TRPV1
engagement in a nonhematopoietic-derived cell population pri-
marily mediates the anti-inflammatory effects of NADA in early
sepsis. However, our studies do not rule out the possibility that the
TRPV1-independent anti-inflammatory effects of NADA on im-
mune and endothelial cells via other receptors, such as CBRs, may
alter outcomes of sepsis, including later complications, such as
multiple organ failure.
Consistent with the cumulative evidence that points to a protective
role for TRPV1 in murine sepsis models, we observe that TRPV1
activation displays a protective phenotype of reduced proin-
flammation, increased anti-inflammation, and downregulation of
PAI-1 in toxicity and infection models of sepsis (17, 27, 39, 40).
However, in contrast to other reports on TRPV1 in sepsis, we did
not detect differences in the cytokine responses of Trpv12/2 and
WT mice treated with LPS or Pam3Cys in the absence of NADA.
Because we used early time points (2–6 h), our study does not
define the role of TRPV1 at later stages of sepsis, which may ac-
count for such differences. Our study suggests the novel possibility
that NADA may regulate sepsis-induced systemic inflammation
through the activation of neuronal TRPV1. The nervous system is
increasingly being recognized as playing key roles in inflammation,
and strong links have been established between the immune and
nervous systems. Neurogenic inflammation is believed to be a
critical component of inflammatory initiation and the pain response
(55, 56). There is also strong evidence that the links between the
nervous and immune systems are bidirectional, with each able to
modulate the activity of the other. In the area of sepsis, current
evidence points to a neuroimmune response mediated through the
vagus nerve and spleen (57, 58). Notably, TRPV1 is expressed in
the vagus nerve, raising the possibility that the vagus nerve might be
involved in the neuroimmune response (59).
Neurogenic inflammation is regulated by neuropeptides, such as
CGRP and substance P, which are released from the peripheral
FIGURE 4. Capsaicin (CAP) and AEA reduce LPS-induced acute in-
flammation in mice. WT mice were challenged i.v. with LPS or carrier and
immediately thereafter were administered CAP [(A–D) 0.2 mg/kg, i.v.],
AEA [(E–H) 40 mg/kg, i.v.], or carrier (i.v.; data not shown) (n = 5–6 mice
per group). Levels of IL-6 (A and E), CCL2 (B and F), IL-10 (C and G), and
PAI-1 (D and H) were quantified in plasmas at 2 h. (A–H) Levels of in-
flammatory mediators and PAI-1 were at baseline in mice treated with CAP
or AEA in the absence of LPS. *p , 0.05, **p , 0.01, LPS-challenged
mice in the presence or absence of CAP or AEA, Mann–Whitney U test.
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terminals of sensory neurons (16). Neuropeptides act in an auto-
crine or paracrine manner on various target cells, such as vascular
endothelial and smooth muscle cells, to regulate vasodilation and
capillary permeability, and on innate and adaptive immune cells to
regulate chemotaxis and activation (16, 56). There is limited in-
formation regarding the importance of neuropeptides in sepsis.
CGRP has been reported to mediate aspects of septic shock in
endotoxemic rats (60). Additionally, elevated levels of plasma
substance P and CGRP have been reported to be associated with
worse outcomes in humans with sepsis (61, 62).
Activation of TRPV1 on pain-sensing neuronal receptors
(nociceptors) by a variety of stimuli promotes the secretion of
CGRP and substance P, which, by inducing inflammation and
vasodilation, facilitate the arrival of circulating leukocytes and
inflammatory mediators to sites of tissue distress (7, 9, 17, 63–68).
However, substance P has also been reported to promote an anti-
FIGURE 5. Nonhematopoietic TRPV1
mediates the anti-inflammatory action of
NADA in endotoxemic mice. (A–D) Irradi-
ated CD45.1+ WT recipient mice were
reconstituted with bone marrow from
CD45.2+ Trpv12/2 mice (Trpv12/2 → WT).
Irradiated CD45.2+ Trpv12/2 recipient mice
were reconstituted with bone marrow from
CD45.1+ WT mice (WT → Trpv12/2) or
Trpv12/2 mice (Trpv12/2 → Trpv12/2).
CD45.2+ WT mice were reconstituted with
CD45.1+ donor bone marrow (WT → WT).
Following engraftment bone marrow chimeras
were challenged i.v. with LPS or vehicle and
5 min later were treated i.v. with NADA (10
mg/kg) or vehicle (n = 6–12 mice per group).
Plasma levels of IL-6 (A), CCL2 (B), IL-10
(C), and PAI-1 (D) were quantified at 2 h. (A–
D) NADA alone did not affect baseline levels
of inflammatory mediators or PAI-1 in any of
the bone marrow chimeras. The Mann–
Whitney U test was used to calculate statis-
tical significance. ***p , 0.001, LPS-treated
mice in the presence or absence of NADA.
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inflammatory wound-healing phenotype by inducing IL-10 and a
switch to M2 macrophages, as well as by inhibiting NO synthase
and TNF-a production (69–71). We observed that the adminis-
tration of NADA increases plasma levels of substance P in a
TRPV1-dependent manner and that LPS augments NADA’s in-
duction of substance P. In contrast, we found that NADA abro-
gates LPS-induced upregulation of CGRP. We postulate that
NADA may exert its anti-inflammatory effects by simultaneously
decreasing CGRP and augmenting substance P in the systemic
circulation, although the effects of NADA on neuropeptide release
and on acute systemic inflammation may be independent of one
another. It is possible that NADA treatment reduced CGRP se-
cretion via the acute desensitization of TRPV1, but this seems
unlikely because, similar to other reports, we observed that NADA
TRPV1-dependently increases levels of substance P in the circu-
lation. Finally, the neuropeptides in the plasma may have been
derived from nonneuronal cells, such as keratinocytes, which have
been shown to express CGRPb, or subsets of leukocytes that ex-
press substance P (69, 72).
In conclusion, we have observed that the administration of
NADA attenuates acute systemic inflammation and coagulopathy
in murine models of acute inflammation and sepsis, and it increases
survival and modulates the levels of circulating neuropeptides in
endotoxemic mice. These in vivo immunomodulatory effects of
NADA appear to be dependent upon TRPV1 expressed in non-
hematopoietic cells. In contrast, NADA modulates inflammatory
activation of primary leukocytes and endothelial cells ex vivo
through receptors and pathways other than TRPV1. These results
suggest that an endogenous NADA–TRPV1 neuronal axis may
dampen the proinflammatory response in the early phases of
sepsis. Further studies will be needed to thoroughly elucidate the
mechanisms by which NADA exerts its effects in vivo, as well as
to determine the role of the NADA–TRPV1 axis in the later phases
FIGURE 6. TRPV1 does not mediate the anti-inflammatory activity of
NADA in LPS-treated hematopoietic cells or endothelial cells ex vivo.
Cultured primary murine bone marrow cells (A), microglia (B), and lung
endothelial cells (C) were treated for 1 h with NADA (1 mM) and then
stimulated with LPS (10 ng/ml) for an additional 6 h in the continued
presence of NADA (n = 4 wells per group). IL-6 levels were quantified in
culture supernatants. Identical results were observed with PBMCs and
thioglycollate-elicited peritoneal macrophages (data not shown). *p ,
0.05, LPS-treated cells in the presence or absence of NADA, Mann–
Whitney U test.
FIGURE 7. NADA regulates neuropeptide release via TRPV1 in
endotoxemic mice. WT and Trpv12/2 mice were challenged i.v. with LPS
or carrier for LPS (normal saline) and then immediately treated i.v. with
NADA (10 mg/kg) or vehicle for NADA. Substance P (A) and CGRP (B)
levels were quantified in plasma at 2 h (n = 4–6 mice per group). The
Mann–Whitney U test was used to calculate statistical significance. *p ,
0.05, LPS-treated WT mice in the presence or absence of NADA. #p ,
0.05, WT mice treated with carrier alone versus WT mice treated with LPS
alone or NADA alone, or mice treated with NADA versus mice treated
with LPS and NADA. dp , 0.05, Trpv12/2 mice treated with carrier alone
versus mice treated with LPS alone, or Trpv12/2 mice treated with NADA
alone versus mice treated with LPS + NADA. NS, no significant between
LPS-treated Trpv12/2 mice in the presence and absence of NADA.
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of sepsis and in sepsis-induced organ injury. Nonetheless, our obser-
vations may have important implications in sepsis and suggest that the
endovanilloid system may represent a unique neuroimmunological
therapeutic target for the treatment of acute systemic inflammation
and sepsis.
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Supplemental Figure 1. NADA ameliorates the induction of pro-inflammatory cytokines and PAI-1 and 
enhances the induction of IL-10 in Pam3Cys-treated mice. WT mice were challenged with Pam3Cys (10 mg/kg, 
i.v.) immediately prior to i.v. administration of NADA (10 mg/kg) or vehicle. Plasma levels of of IL-6 (a), 
CCL2 (b), IL-10 (c) and PAI-1 (d) were quantified 2 hours after Pam3Cys challenge. **, p < 0.01 (Mann-
Whitney test; n = 4-6 mice per group). Vehicle-treated mice had background levels of all cytokines (data not 
shown). 
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Supplemental Figure	  2.  The half-life of NADA in plasma is in the order of minutes. Plasma concentrations of 
NADA were quantified in the plasmas of WT mice by LC-MS/MS at intervals from t = 0-60 minutes after i.v. 
administration of NADA (10 mg/kg). 
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Supplemental Figure	  3. 2-arachidonoyl glycerol (2-AG) does not affect the induction of cytokines or PAI-1 in 
endotoxemic mice. WT mice were challenged i.v. with LPS or carrier, and immediately after were administered 
i.v. 2-AG (10 mg/kg) or vehicle. Levels of IL-6 (A), CCL2 (B) and PAI-1 (C) were quantified in plasmas at 2 
hours. 2-AG did not affect baseline levels of inflammatory mediators or PAI-1 alone or in the presence of LPS. 
NS, not significant (Mann-Whitney test; n = 4 mice per group). 
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